UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, Tolerability, and Efficacy of Hizentra Over An Extended Period for the Treatment of Primary Immunodeficiency Disease

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB83-AB83

2012

Volltextzugriff (PDF)

Food Allergy Quality of Life (FAQOL) Is Improved For Food Oral Immunotherapy (OIT) Treated Patients and Their Families

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB29-AB29

2012

Volltextzugriff (PDF)

Subcutaneous Immunoglobulin Replacement Therapy for Primary Immunodeficiency: High-Dose versus Low-Dose Treatment using Hizentra

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB214-AB214

2011

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB203-AB203

2012

Volltextzugriff (PDF)

Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB15-AB15

2012

Volltextzugriff (PDF)

Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB14-AB14

2012

Volltextzugriff (PDF)

Peanut Oral Immunotherapy (OIT) of Food Allergy (FA) Carries a Significant Risk of Eosinophilic Esophagitis (EoE)

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB28-AB28

2011

Volltextzugriff (PDF)

Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB213-AB213

2011

Volltextzugriff (PDF)

Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB15-AB15

2011

Volltextzugriff (PDF)

Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB15-AB15

2011

Volltextzugriff (PDF)

Oral Immunotherapy (OIT) of Food Allergy (FA) Successfully Desensitizes Most Patients

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB25-AB25

2011

Volltextzugriff (PDF)

New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD)

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB16-AB16

2011

Volltextzugriff (PDF)

Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB17-AB17

2011

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Subcutaneous Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients with Primary Immunodeficiency Disease (PID)

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB140-AB140

2010

Volltextzugriff (PDF)

(1) An Office Based, One Day Rush Immunotherapy (1DRIT) Protocol for Pollens and Environmental Aeroallergens in Children

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S61-S61

2009

Volltextzugriff (PDF)

Office Based Oral Desensitization of Patients With Anaphylactic Sensitivity to Foods Is Safe and Effective

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB59-AB59

2010

Volltextzugriff (PDF)

Office Based Oral Desensitization of Patients With Non-Anaphylactic Sensitivity to Foods Is Safe and Effective

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB21-AB21

2010

Volltextzugriff (PDF)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients with Primary Immunodeficiency

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB140-AB140

2010

Volltextzugriff (PDF)

Evaluation of Prodromal Symptoms Concurrent with Hereditary Angioedema Therapy

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S100-S100

2009

Volltextzugriff (PDF)

IGIV-10% Infused Intravenously And Subcutaneously To Subjects With Primary Immunodeficiency Diseases - Comparison Of Pharmacokinetic Properties

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S11-S11

2009

Volltextzugriff (PDF)

Pharmacokinetics of IgPro20 after Subcutaneous Administration in Patients with Primary Immunodeficiency

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB145-AB145

2010

Volltextzugriff (PDF)

C1 Esterase Inhibitor Concentrate (C1-INH) for the Treatment of Acute Attacks of Hereditary Angioedema: Interim Results of an Ongoing, Prospective, Open Label Study in North America after 640 attacks (I.M.P.A.C.T.2)

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S99-S99

2009

Volltextzugriff (PDF)

Recombinant Human Hyaluronidase Facilitates Dispersion of Subcutaneously Administered Gammagard Liquid and Enables Administration of a Full Monthly Dose in a Single Site to Patients with Immunodeficiency Diseases

Journal of allergy and clinical immunology, 2008-02, Vol.121 (2), p.S83-S83

2008

Volltextzugriff (PDF)

Pharmacokinetics of a Novel Liquid 10% Immunoglobulin Preparation for Intravenous Use (Privigen) in Subjects with Primary Immunodeficiency

Journal of allergy and clinical immunology, 2008-02, Vol.121 (2), p.S168-S168

2008

Volltextzugriff (PDF)

Safety and Tolerability of a New Intravenous Immunoglobulin Product (Privigen) Administered at High Infusion Rates

Journal of allergy and clinical immunology, 2008-02, Vol.121 (2), p.S165-S165

2008

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(59)
Buchkapitel
(4)

Sprache

Englisch
(62)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Allergy And Immunology
(26)
Science & Technology
(14)
Life Sciences & Biomedicine
(10)
Medical Research
(6)
Astronomy
(5)
Drug Therapy
(5)
Earth, Ocean, Space
(5)
Exact Sciences And Technology
(5)
Patients
(5)
Planets, Their Satellites And Rings. Asteroids
(5)
Solar System
(5)
Allergies
(4)
Animals
(4)
Astronomy & Astrophysics
(4)
Food
(4)
Humans
(4)
Infections
(4)
Physical Sciences
(4)
Asteroids
(3)
Biological And Medical Sciences
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, Tolerability, and Efficacy of Hizentra Over An Extended Period for the Treatment of Primary Immunodeficiency Disease

Food Allergy Quality of Life (FAQOL) Is Improved For Food Oral Immunotherapy (OIT) Treated Patients and Their Families

Subcutaneous Immunoglobulin Replacement Therapy for Primary Immunodeficiency: High-Dose versus Low-Dose Treatment using Hizentra

Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)

Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)

Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)

Peanut Oral Immunotherapy (OIT) of Food Allergy (FA) Carries a Significant Risk of Eosinophilic Esophagitis (EoE)

Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

Oral Immunotherapy (OIT) of Food Allergy (FA) Successfully Desensitizes Most Patients

New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD)

Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Pharmacokinetics and Safety of Subcutaneous Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients with Primary Immunodeficiency Disease (PID)

(1) An Office Based, One Day Rush Immunotherapy (1DRIT) Protocol for Pollens and Environmental Aeroallergens in Children

Office Based Oral Desensitization of Patients With Anaphylactic Sensitivity to Foods Is Safe and Effective

Office Based Oral Desensitization of Patients With Non-Anaphylactic Sensitivity to Foods Is Safe and Effective

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients with Primary Immunodeficiency

Evaluation of Prodromal Symptoms Concurrent with Hereditary Angioedema Therapy

IGIV-10% Infused Intravenously And Subcutaneously To Subjects With Primary Immunodeficiency Diseases - Comparison Of Pharmacokinetic Properties

Pharmacokinetics of IgPro20 after Subcutaneous Administration in Patients with Primary Immunodeficiency

C1 Esterase Inhibitor Concentrate (C1-INH) for the Treatment of Acute Attacks of Hereditary Angioedema: Interim Results of an Ongoing, Prospective, Open Label Study in North America after 640 attacks (I.M.P.A.C.T.2)

Recombinant Human Hyaluronidase Facilitates Dispersion of Subcutaneously Administered Gammagard Liquid and Enables Administration of a Full Monthly Dose in a Single Site to Patients with Immunodeficiency Diseases

Pharmacokinetics of a Novel Liquid 10% Immunoglobulin Preparation for Intravenous Use (Privigen) in Subjects with Primary Immunodeficiency

Safety and Tolerability of a New Intravenous Immunoglobulin Product (Privigen) Administered at High Infusion Rates

Suchergebnisse filtern